Yubo International Biotech Ltd
Yubo International Biotech is a U.S. holding company whose day-to-day operations in China are conducted by Yubo Beijing, a variable interest entity managed through contractual arrangements. Yubo Beijing focuses on the research, development and application of endometrial stem cells and offers products and services under the VIVCELL brand. Its products include respiratory healthcare products, skincare and hair care products, healthy beverages, and male and female personal care products. It also provides cell testing and health management consulting services. Yubo Beijing makes money through sales of its products and provision of stem cell-related services. The contractual arrangements entitle the WFOE to 90% of Yubo Beijing’s after-tax profit annually, though Yubo Beijing has not paid a fee under the arrangement to date. Yubo International Biotech is headquartered in Beijing, China.
No enriched coverage for $YBGJ in the last 7 days.
No SEC Form 4 filings for $YBGJ in the last 30 days.
See all $YBGJ insider activity →Yubo International Biotech reported no revenue and zero earnings per share in Q3 2026, consistent with the prior year. The net loss decreased due to lower operating expenses, despite higher other expenses. Operating costs fell 34.4% to $203,388, driven by reduced depreciation, employee compensation, and occupancy expenses. The company continued market research and explored sales channels.
Yubo International Biotech reported no revenue and zero earnings per share in Q3 2026, consistent with the prior year. The net loss decreased due to lower operating expenses, despite higher other expenses. Operating costs fell 34.4% to $203,388, driven by reduced depreciation, employee compensation, and occupancy expenses. The company continued market research and explored sales channels.
AlphAI scores every news story that mentions YBGJ with an AI model for sentiment and relevance, and aggregates insider trades from Yubo International Biotech Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Yubo International Biotech reported no revenue and zero earnings per share in Q3 2026, consistent with the prior year. The net loss decreased due to lower operating expenses, despite higher other expenses. Operating costs fell 34.4% to $203,388, driven by reduced depreciation, employee compensation, and occupancy expenses. The company continued market research and explored sales channels.
